CRVO Company Profile and Key Details

CervoMed Inc. has 15.12 million shares outstanding. The public float is 9.60 million shares, elevated short interest at 10.88% of float. This equals 1.33 million shares. The short ratio is 3.9 days. Institutional investors hold 27.13% of the float. Insiders own 29.54%. BOGER JOSHUA S holds 955.41 thousand shares, Winton Matthew has 15.00 thousand shares and Gregoire Sylvie has 12.50 thousand shares. Over the past six months, insider transactions show net buying. They sold 0.00 shares across 0 transactions.

CRVO has shown weak momentum, losing -7.91% over the past week and -1.27% over the past quarter, though year-to-date performance is down -11.52%. Short-term trend indicators are bullishly aligned (SMA20 -9.09%, SMA50 -31.38%, SMA200 -43.15%). The stock’s 14-day RSI is 36.08 (weak momentum), while the ATR of 0.47 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -74.03% below its high and over 129.17% above its low. Average 10-day trading volume of 165.51 thousand shares is below the 3-month average of 2.25 million, indicating normal recent market interest.

CervoMed Inc. generated EPS of -$2.90 over the past year. Five-year average earnings growth is 56.66%. Wall Street analysts project EPS growth of 10.68% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 19 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $31.00 to $11.00. The high target offers 1115.69% upside. The low target suggests 331.37% downside. The mean target is $26.68. This offers 946.27% upside. CervoMed Inc. earnings surprise history is a mixed track record. The quarter that ended August 10, 2026, missed forecasts by -19.69%. The prior quarter beat by -26.44%. Over the last six quarters, Apple has recorded several small beats. These include 23.53% in November 07, 2025.

CervoMed Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.91. This means the shares are trading above this model’s fair value.

CervoMed Inc. (NASDAQ:CRVO) closed at $2.55 USD, gaining $0.11 (4.51%) from the previous close of $2.44. The stock is currently mid-range between its 52-week high and low $2.13 and $10.00. With a market capitalization of about $23.61 million, CervoMed Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~-4.31). Key stats such as the average daily volume over the past year has been around 2.25 million shares, volume is running light vs its 52-week average. Headquartered in Boston, MA, CervoMed Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO John J. Alam, the company employs approximately 15 people and listed since May 23, 2008. CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders.

CervoMed Inc. trades at a P/E ratio of -0.8, slightly below the S&P 500 average, with a price-to-sales ratio of 74.05 and a price-to-book ratio of 1.15 suggesting the stock is closer to book value. The P/FCF stands at -0.85, also above market averages.

Our AI price prediction model suggests that CervoMed Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -9.8%, with price expected at $2.30 by September 30, 2026, within a range of $2.16 to $2.42 3-Month Outlook: Projected fall of -69.02%, reaching $0.79 by December 15, 2026, with a range of $0.38 to $1.14. 1-Year Outlook: Projected loss of -78.82%, with price at $0.54 by September 16, 2027, within a range of $0.00 to $0.00.

CervoMed Inc. (NASDAQ:CRVO) shares are down -11.52% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows CervoMed Inc. trading at a premium to the broader market with a P/E of -0.8. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $25.75, suggesting 909.8% upside. Our AI forecast model points to short-term weakness (-9.8% over two weeks), a medium-term fall (-69.02% over three months), and a longer-term loss (-78.82% over one year), with expected trading ranges indicating moderate volatility.